Volume 9, Issue 8, Pages 743-750 (August 2017) A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics Natalie S. Schmitz, PharmD, Linda E. Krach, MD, Lisa D. Coles, PhD, Usha Mishra, MS, Suresh K. Agarwal, PhD, James C. Cloyd, PharmD, Robert L. Kriel, MD PM&R Volume 9, Issue 8, Pages 743-750 (August 2017) DOI: 10.1016/j.pmrj.2016.11.002 Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Figure 1 Subject participation. PM&R 2017 9, 743-750DOI: (10.1016/j.pmrj.2016.11.002) Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Figure 2 Mean (± standard deviation) change from baseline sedation scores after 20-mg PO and 15-mg 10-minute and 60-minute infusions (n = 12). PM&R 2017 9, 743-750DOI: (10.1016/j.pmrj.2016.11.002) Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Figure 3 Maximum increase in sedation score by route of administration and dose. PM&R 2017 9, 743-750DOI: (10.1016/j.pmrj.2016.11.002) Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Figure 4 Mean (± standard deviation) plasma-concentration time profiles after oral (PO) and intravenous (IV) baclofen (n = 12 for each baclofen dose). PM&R 2017 9, 743-750DOI: (10.1016/j.pmrj.2016.11.002) Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Figure 5 Effect of route of administration and dose on maximum concentration (Cmax) and AUC(0-inf) (mean ± standard deviation). Cmax = maximum concentration; AUC(0-inf) = Area Under the Curve 0 to infinity. PM&R 2017 9, 743-750DOI: (10.1016/j.pmrj.2016.11.002) Copyright © 2017 American Academy of Physical Medicine and Rehabilitation Terms and Conditions